Literature DB >> 1546127

Safety of moclobemide taken in overdose for attempted suicide.

W Hetzel1.   

Abstract

Moclobemide is a reversible inhibitor of the monoamine oxidase type A. In clinical studies, more than 3900 patients have been treated with moclobemide for depression. Eighteen of these patients attempted suicide by overdosing moclobemide with or without other drugs. All patients recovered fully without leaving signs of cardio- or hepatotoxicity. Moclobemide can safely be prescribed for in- and out-patient treatment of depression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546127     DOI: 10.1007/bf02246256

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  4 in total

1.  Fatal toxicity of antidepressant drugs in overdose.

Authors:  S Cassidy; J Henry
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-24

Review 2.  Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.

Authors:  M Da Prada; R Kettler; H H Keller; W P Burkard; W E Haefely
Journal:  J Neural Transm Suppl       Date:  1989

3.  Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.

Authors:  M Versiani; A E Nardi; I L Figueira; M Stabl
Journal:  Acta Psychiatr Scand Suppl       Date:  1990

4.  Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.

Authors:  P R Bieck; K H Antonin
Journal:  J Neural Transm Suppl       Date:  1989
  4 in total
  5 in total

Review 1.  Serotonin syndrome and drug combinations: focus on MAOI and RIMA.

Authors:  S E Hilton; H Maradit; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Antidepressant toxicity and the need for identification and concentration monitoring in overdose.

Authors:  B M Power; L P Hackett; L J Dusci; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

3.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.

Authors:  Geoffrey K Isbister; L P Hackett; Andrew H Dawson; Ian M Whyte; Anthony J Smith
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 4.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 5.  A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Authors:  T R Norman; G D Burrows
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.